<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and Crohn's <z:e sem="disease" ids="C0009373" disease_type="Disease or Syndrome" abbrv="">colonic disease</z:e> are at increased risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the study was to analyze the methylation status of selected genes as a risk marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We evaluated the methylation status of four genes (TGFB2, SLIT2, HS3ST2, and TMEFF2) in biopsies of four groups of patients: 60 patients with <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 32 patients with IBD-associated <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, 85 patients with IBD without associated <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (20 at high risk and 65 at low risk), and 28 healthy controls </plain></SENT>
<SENT sid="3" pm="."><plain>Methylation-specific melting curve analysis (MS-<z:chebi fb="70" ids="34342">MCA</z:chebi>) was used </plain></SENT>
<SENT sid="4" pm="."><plain>Methylation status of these genes was also assessed in stool DNA from 60 IBD patients without <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Methylation of the panel of genes analyzed was a very common phenomenon (78%) in IBD-associated <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The prevalence of methylation in adjacent nonneoplastic mucosa was also high (12/30) </plain></SENT>
<SENT sid="7" pm="."><plain>This prevalence was higher than in mucosa from healthy controls (2/28;7.1%; P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Methylation of SLIT2 and TMEFF2 was more frequently detected in the mucosa of IBD patients at high risk of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (15/20) than patients at low risk (32/63) (P = 0.05 and P = 0.03, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>When stool samples were assessed, only SLIT2 gene methylation was more frequently methylated in the group of patients at high risk of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (4/16) compared to low risk (0/37) (P = 0.006) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Analysis of a panel of methylation markers may help in the early identification of colorectal <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in high-risk IBD patients </plain></SENT>
</text></document>